Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

The Global IV and Oral Iron Drugs Market Sees Explosive Growth, the Market to Reach $16.34 Billion by 2029 - Arizton

This image opens in the lightbox

News provided by

Arizton Advisory & Intelligence

23 Jan, 2024, 19:50 GMT

Share this article

Share toX

Share this article

Share toX

CHICAGO, Jan. 23, 2024 /PRNewswire/ -- According to Arizton's latest research report, the global IV and Oral Iron Drugs market is growing at a CAGR of 13.47% during 2023-2029.

To Know More, Download the Free Sample Report: https://www.focusreports.store/request-sample/iv-and-oral-iron-drugs-market-focused-insights

Continue Reading
This image opens in the lightbox
Global IV & Oral Iron Drugs Market Focus Insight Report by Arizton

IV and Oral Iron Drugs Market Report Scope

Report Attributes

Details

Market Size (2029)

$16.34 billion

CAGR (2022-2029)

13.47 %

Historic Year

2022-2021

Base Year

2022

Forecast Year

2023-2029

Market Segmentation

Route of administration, patient group, distribution channel, application


The North America is the largest market for the global IV and oral iron drugs market. The growing prevalence of Iron Deficiency Anemia is fueling the market's demand for intravenous (IV) and oral iron drugs. This condition is widespread among specific populations such as pregnant women, women of reproductive age, and individuals with chronic diseases. Increased awareness about iron deficiency anemia and the proven effectiveness of iron drugs in its treatment has contributed to a surge in demand for these medications. To thrive in this fiercely competitive market, it is crucial for manufacturers to continually develop and introduce innovative products, ensuring robust sales growth and an expanded market share. New entrants in the industry should concentrate on providing cost-effective, advanced-generation IV and oral iron drugs with improved efficacy to establish a foothold in this competitive landscape.

The global IV & oral iron drugs market is highly competitive, with prominent players offering a broad range of branded and generic IV & oral iron drugs for end-users. The market is characterized by the presence of a few global and several regional and local players offering branded and generic iron drugs. With significant shares, Vifor Pharma and Daiichi Sankyo Company are the leading players in the global IV & oral iron drugs market. In addition, AMAG Pharmaceuticals, PHARMACOSMOS, Sanofi, Allergan, Akebia Therapeutics, and Shield Therapeutics are other prominent players in the market with notable shares. Key players are expected to drive sales and margin growth in their business by expanding sales organization, maintaining technology leadership through R&D, and continuously creating clinical evidence to support product benefits and services. Currently, the market competitiveness among vendors is high due to the availability of a wide array of low-cost generic drug formulations for treating ID. Companies offering branded iron drugs are registering impressive growth rates for their products due to the increased uptake of branded IV iron drugs.

Online Retailers Revolutionizing the IV & Oral Iron Drug Market

In 2023, the online channels segment constituted 11.76% of the market share, predominantly driven by the presence of online retailers. This category has evolved into a popular avenue for the distribution of iron drugs. According to projections from Arizton, this segment is poised for an absolute growth rate of 71.32% throughout the forecast period. The convenience of ordering specific prescription or generic iron drugs online and having them delivered to one's doorstep eliminates the need for physical store visits. The increasing adoption of iron drugs, fueled by the rising incidence of Iron Deficiency (ID) and Iron Deficiency Anemia (IDA), is expected to drive the demand for these products in the years ahead. Introducing reputable retailers' e-commerce and online distribution channels disrupt traditional iron drug sales channels.

Additionally, digital technology is addressing challenges in existing paths to purchase. Notably, online ordering provides a convenient option for customers, particularly the working and elderly populations, who can order products according to their schedules without visiting physical stores. Consumers now have the flexibility to choose from a diverse array of iron products, spanning various brands and price points, accessible at their fingertips. This accessibility has empowered consumers to make informed decisions, showcasing their sophistication in selecting iron drugs tailored to their specific requirements. Furthermore, the online platform offers opportunities for smaller vendors to thrive in the market, allowing them to compete on an equal footing with significant players by promoting their products on the same platform.

Buy this Research @ https://www.focusreports.store/report/iv-and-oral-iron-drugs-market-focused-insights

The Following Market Segment Analysis is Included in this Report

  • Route of Administration
  • Intravenous
  • Oral
  • Patient Group
  • Adults
  • Pediatrics
  • Distribution Channel
  • Hospital Pharmacies
  • Offline Retail Pharmacies
  • Online Channels
  • Application
  • Nephrology
  • Obstetrics & Gynaecology
  • Surgery
  • Gastroenterology
  • Oncology
  • Heart Failure

Vendors List

  • CSL Vifor
  • Daiichi Sankyo
  • Covis Pharmaceuticals
  • Akebia Therapeutics
  • Shield Therapeutics
  • Pharmacosmos
  • AbbVie
  • Sanofi
  • AOP Orphan Pharmaceuticals
  • Azad Pharmaceuticals
  • Pfizer
  • Ciron Drugs & Pharmaceuticals
  • Rockwell Medical
  • Salveo Lifecare
  • Sunny Pharmaceuticals
  • Zydus LifeSciences
  • Nippon Shinyaku
  • Alinter Group
  • Alora Pharmaceuticals
  • DSE Healthcare
  • GSK plc

Key Questions Answered in the Report:

What is the projected value of the global IV and Oral Iron Drugs market by 2029?

What is the growth rate of the IV and Oral Iron Drugs market?

What are the primary drivers of this market growth?

Who are the leading players in the IV and Oral Iron Drugs market?

Table of Contents

CHAPTER – 1: IV & Oral Iron Drugs Market Overview

  • Executive Summary
  • Key Findings

CHAPTER – 2: IV & Oral Iron Drugs Market

  • GLOBAL: Projected Revenue of IV & Oral Iron Drugs Market (2023-2029; $Billions)

CHAPTER – 3: IV & Oral Iron Drugs Market Segmentation Data

  • GLOBAL: Projected Revenue by Route of Administration (2023-2029; $Billions)
  • Intravenous
  • Oral
  • GLOBAL: Projected Revenue by Patient Group (2023-2029; $Billions)
  • Adults
  • Pediatrics
  • GLOBAL: Projected Revenue by Distribution Channel (2023-2029; $Billions)
  • Hospital Pharmacies
  • Offline Retail Pharmacies
  • Online Channels
  • GLOBAL: Projected Revenue by Application (2023-2029; $Billions)
  • Nephrology
  • Obstetrics & Gynecology
  • Surgery
  • Gastroenterology
  • Oncology
  • Heart Failure

CHAPTER – 4: Key Regions Overview

  • North America: Projected Revenue of IV & Oral Iron Drugs Market (2023-2029; $Billions)
  • Projected Revenue of IV & Oral Iron Drugs Market in US
  • Projected Revenue of IV & Oral Iron Drugs Market in Canada
  • Europe: Projected Revenue of IV & Oral Iron Drugs Market (2023-2029; $Billions)
  • Projected Revenue of IV & Oral Iron Drugs Market in Germany
  • Projected Revenue of IV & Oral Iron Drugs Market in UK
  • Projected Revenue of IV & Oral Iron Drugs Market in France
  • Projected Revenue of IV & Oral Iron Drugs Market in Italy
  • Projected Revenue of IV & Oral Iron Drugs Market in Spain
  • APAC: Projected Revenue of IV & Oral Iron Drugs Market (2023-2029; $Billions)
  • Projected Revenue of IV & Oral Iron Drugs Market in Japan
  • Projected Revenue of IV & Oral Iron Drugs Market in China
  • Projected Revenue of IV & Oral Iron Drugs Market in Australia
  • Latin America: Projected Revenue of IV & Oral Iron Drugs Market (2023-2029; $Billions)
  • Projected Revenue of IV & Oral Iron Drugs Market in Brazil
  • Projected Revenue of IV & Oral Iron Drugs Market in Mexico
  • Projected Revenue of IV & Oral Iron Drugs Market in Argentina
  • Middle East & Africa: Projected Revenue of IV & Oral Iron Drugs Market (2023-2029; $Billions)
  • Projected Revenue of IV & Oral Iron Drugs Market in Turkey
  • Projected Revenue of IV & Oral Iron Drugs Market in South Africa
  • Projected Revenue of IV & Oral Iron Drugs Market in Saudi Arabia

CHAPTER – 5: IV & Oral Iron Drugs Market Prospects & Opportunities

  • IV & Oral Iron Drugs Market Opportunities & Trends
  • IV & Oral Iron Drugs Market Drivers
  • IV & Oral Iron Drugs Market Constraints

CHAPTER – 6: IV & Oral Iron Drugs Industry Overview

  • IV & Oral Iron Drugs Market - Competitive Landscape
  • IV & Oral Iron Drugs Market – Key Vendor Profiles
  • IV & Oral Iron Drugs Market – Other Prominent Vendors
  • IV & Oral Iron Drugs Market - Key Strategic Recommendations

CHAPTER – 7: Appendix

  • Research Methodology
  • Abbreviations
  • About Arizton

About Focused Reports by Arizton   

Welcome to Focused Reports, an esteemed Arizton Advisory & Intelligence subsidiary committed to delivering precise and insightful market research reports across all key geographies. Our unique selling proposition lies in our affordable pricing, accurate data, in-depth research, and presentation-ready reports. With us, expensive market research is a thing of the past. We aim to be strategic, providing valuable data. Focus Reports is where folks come to name their ideas, create a compelling brand and a great-looking website, and attract customers with digital and social marketing.    

Contact Us:   

Call: +1-312-235-2040                                              
          +1 302 469 0707                                             
Mail: enquiry@arizton.com  

Website: https://www.focusreports.store/   

Photo: https://mma.prnewswire.com/media/2324626/Global_IV_Oral_Iron_Drugs.jpg
Logo: https://mma.prnewswire.com/media/818553/Arizton_Logo.jpg

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.